title: Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
abstract: The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.
authors: Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, Austria. heinz.ludwig@wienkav.at
authors: Heinz
authors: H
authors: Ludwig
authors: Meral
authors: M
authors: Beksac
authors: Joan
authors: J
authors: Bladé
authors: Jamie
authors: J
authors: Cavenagh
authors: Michele
authors: M
authors: Cavo
authors: Michel
authors: M
authors: Delforge
authors: Meletios
authors: M
authors: Dimopoulos
authors: Johannes
authors: J
authors: Drach
authors: Hermann
authors: H
authors: Einsele
authors: Thierry
authors: T
authors: Facon
authors: Hartmut
authors: H
authors: Goldschmidt
authors: Jean-Luc
authors: JL
authors: Harousseau
authors: Urs
authors: U
authors: Hess
authors: Martin
authors: M
authors: Kropff
authors: Fernando
authors: F
authors: Leal da Costa
authors: Vernon
authors: V
authors: Louw
authors: Hila
authors: H
authors: Magen-Nativ
authors: Larisa
authors: L
authors: Mendeleeva
authors: Hareth
authors: H
authors: Nahi
authors: Torben
authors: T
authors: Plesner
authors: Jesús
authors: J
authors: San-Miguel
authors: Pieter
authors: P
authors: Sonneveld
authors: Miklos
authors: M
authors: Udvardy
authors: Pia
authors: P
authors: Sondergeld
authors: Antonio
authors: A
authors: Palumbo
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D015897:Comorbidity; D003226:Congresses as Topic; D018572:Disease-Free Survival; D005060:Europe; D055317:Evidence-Based Practice; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide